Timothy P. Noyes - Nov 1, 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Stock symbol
AVTE
Transactions as of
Nov 1, 2022
Transactions value $
-$20,241
Form type
4
Date filed
11/3/2022, 05:00 PM
Previous filing
Dec 16, 2021
Next filing
Dec 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Sale -$20.2K -1.04K -100% $19.50 0 Nov 1, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2022.
F2 Includes 1,038 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on October 31, 2022 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).